Equities

Tibet Weixinkang Pharmaceutical Co Ltd

603676:SHH

Tibet Weixinkang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)10.55
  • Today's Change-0.21 / -1.95%
  • Shares traded6.51m
  • 1 Year change-3.30%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments895806712
Total Receivables, Net187227195
Total Inventory383323
Prepaid expenses807380
Other current assets, total------
Total current assets1,2001,1391,009
Property, plant & equipment, net380359328
Goodwill, net------
Intangibles, net586282
Long term investments767162
Note receivable - long term------
Other long term assets------
Total assets1,7771,6651,496
LIABILITIES
Accounts payable229237245
Accrued expenses444432
Notes payable/short-term debt000
Current portion long-term debt/capital leases3.862.312.47
Other current liabilities, total118128141
Total current liabilities395412419
Total long term debt3.823.482.35
Total debt7.685.794.81
Deferred income tax3.460.46--
Minority interest00--
Other liabilities, total34286.70
Total liabilities437444428
SHAREHOLDERS EQUITY
Common stock435435436
Additional paid-in capital347341319
Retained earnings (accumulated deficit)580454347
Treasury stock - common(22)(24)(53)
Unrealized gain (loss)0.7814--
Other equity, total----19
Total equity1,3401,2211,067
Total liabilities & shareholders' equity1,7771,6651,496
Total common shares outstanding435435436
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.